English Ukrainian
Clinical medicine

PREDICTION OF HEPATIC FIBROSIS PROGRESSION RATE IN CHRONIC HEPATITIS C ON THE BASIS OF CLINICAL AND GENETIC SIGNS

Published 2019-10-16

Authors:

L.M. Syzova
L.T. Koval
V.A. Bodnar
I.P. Kaydashev
O.М. Izyumska
Abstract:
A cross-sectional study of 166 patients with chronic hepatitis C was carried out. As a result of the analysis, among the 35 possible factors of rapid progression of hepatic fibrosis in chronic hepatitis C, 10 most informative ones were identified: male gender (p=0.005), 1 genotype of HCV (p=0.040), alanine aminotransferase above 3 upper limits of normal (p=0.015), the levels of aspartate aminotransferase, γ-glutamyltranspeptidase and total bilirubin exceeding the upper limit of normal (p=0.000, p=0.000 and p=0.001, respectively), alcohol consumption >40 g/day (p=0.033), chronic cholecystitis and/or pancreatitis (p=0.000), type II diabetes mellitus (p=0.007) and a carriage of the normal genotype (Gln/Gln, Gln/-) of the TLR7 gene (p=0.001). In order to optimize the prognostication of the affiliation of a patient with chronic hepatitis C to the risk group of rapid progression of hepatic fibrosis there were proposed the highly effective mathematical model, developed on the basis of multiple discriminant analysis, exact forecast of which was 82.5 %.
Keywords:
chronic hepatitis C the rate of fibrosis progression prognostic model discriminant analysis
References:
  1. Dubynska HM, Syzova LM, Koval TI, Iziumska OM. Vplyv polimorfizmu heniv TLR4 ta TLR7 na shvydkist prohresuvannia fibrozu pechinky u khvorykh na khronichnyi hepatyt С. Hepatolohiia. 2016;1(31):23-32. [in Ukrainian].
  2. Kozko VM, Antsyferova NV, Solomennyk AO, Kopiychenko YaI. Ohliad etiolohii ta kliniky khronichnoi formyHCV-infektsii. Eksperymentalna i klinichna medytsyna. 2012; 1(54):142-145. [in Ukrainian].
  3. Musin AG, Mutalova EG, Nigmatullina AE, Konstantinova EE, MusinaFS, Nasibullin IM. Sovremennye aspekty mekhanizmov fibrogeneza v pecheni. Meditsinskiy vestnik Bashkortostana. 2014; 9(3):95-99. [in Russian].
  4. Sheptulina AF, Shirokova YeN, IvashkinVT. Neinvazivnaya diagnostika fibroza pecheni: rol syvorotochnyh markerov. Ros. zhurn. Gastroehnterol., 2015;2:28-40. [in Russian].
  5. Askar E, Ramadori G, Mihm S. Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection. J Med Virol., 2010;82(11):1859-1868. doi: 10.1002/jmv.21893
  6. Dubinskaya G, Sizova L, Koval Т, Kovalyova Е, Kaydashev I. Clinical and genetic predictors and prognostic model of rapidly progressive hepatic fibrosis in chronic hepatitis C. Georgian Med News. 2016;7-8(256-257):37-45.
  7. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:53-194.
  8. Elsedawy YS, Khattab MA, El Hady SA, El Sayed AA, Albreedy, AM, Hefny ZM. Single nucleotide polymorphisms of Toll-like receptor 7 in hepatitis C virus infection and hepatocellular carcinoma patients. The Egyptian Journal of Medical Microbiology. 2016;38(105):1-8. doi: 10.12816/0037023
  9. Fakhir FZ, Lkhider M, Badre W, Alaoui R, Meurs EF, Pineau P, et al. Genetic variations in toll-like receptors 7 and 8 modulate natural hepatitis C outcomes and liver disease progression. Liver Int. 2018; 38(3): 432-442. doi: 10.1111/liv.13533
  10. Gudowska M, Wojtowicz E, Cylwik B, Gruszewska E, Chrostek L. The distribution of liver steatosis, fibrosis, steatohepatitis and inflammation activity in alcoholics according to FibroMax Test. Adv Clin Exp Med., 2015; 24(5):823-827. doi: 10.17219/acem/28485
  11. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. World Health Organization; 2016.138 p.
  12. Howell J, Angus P, Gow P, Visvanathan K. Toll-like receptors in hepatitis C infection: Implications for pathogenesis and treatment. J Gastroenterol Hepatol. 2013;28(5):766-76. doi: 10.1111/jgh.12170
  13. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. doi: 10.1002/hep.27259
  14. Poynard T, Bedossa Р, Opolon Р. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOS-VIRC groups. Lancet.1997;349(9055):825-832.
  15. Xu Y, Zhong J. Innate immunity against hepatitis C virus. Curr Opin Immunol. 2016;42:98-104. doi: 10.1016/j.coi.2016.06.009
Publication:
«World of Medicine and Biology» Vol. 15 No. 70 (2019) , с. 151-155
УДК 616.36-006.327-036-06:616.36-002.14/2:612.6.05
DOI:
https://doi.org/10.26724/2079-8334-2019-4-70-151-155